-+ 0.00%
-+ 0.00%
-+ 0.00%

ABVC BioPharma Reveals Receipt Of $200K Cash Payment From OncoX BioPharma As Part Of Its Strategic Licensing Agreement For Certain Oncology-related Products

Benzinga·12/11/2024 11:32:44
Listen to the news

This payment marks the first installment of $5 million in potential licensing fees from OncoX.

With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and Rgene Corporation are each eligible to receive up to 10M OncoX shares, $5M cash payment, and royalties up to $50M after the product launches.